Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omeprazole magnesium is the magnesium salt form of omeprazole, a substituted benzimidazole and selective proton pump inhibitor (PPI). It acts by irreversibly inhibiting the gastric parietal cell H+/K+ adenosine triphosphatase (proton pump), which is the final step in gastric acid production. This leads to a marked reduction in both basal and stimulated gastric acid secretion. Omeprazole magnesium is used for short-term treatment of active duodenal ulcers, eradication of Helicobacter pylori to reduce ulcer recurrence risk, treatment of benign gastric ulcers, symptomatic gastroesophageal reflux disease (GERD), erosive esophagitis due to acid-mediated GERD, maintenance healing of erosive esophagitis, and pathologic hypersecretory conditions such as Zollinger-Ellison syndrome. The drug is available as delayed-release oral capsules or granules for suspension[4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omeprazole magnesium.